Skip to content

Person-checked company records fromPerson-checked records $750See a worked exampleHuman review in progress

Talk to sales

KeptIndex

Panbela Therapeutics, Inc.

Initiate a randomized clinical trial for SBP-101

Delivered after the deadline

AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.

Announced
10 Feb 2021
Due
30 Jun 2021
Delivered
January 2022
  • Deadline
  • Met
  • Late
  • Not met
  • Today

What the company said

“working with the FDA to initiate a randomized trial mid-year.”

What we found

Evidence strength A What the grades mean

The company committed to initiating a randomized clinical trial by mid-year 2021, but filings confirm the trial was not initiated until January 2022.

  • A
    Panbela Therapeutics, Inc. 10-Q filed 2021-08-11 Regulatory filing · published 11 Aug 2021 · retrieved 25 Oct 2026 · kept permanently by the SEC · fingerprint e59f5ae967f2
    “initiating a planned randomized trial to be started in the second half of 2021” ✓ confirmed on the page
  • A
    Panbela Therapeutics, Inc. 10-K filed 2022-03-24 Regulatory filing · published 24 Mar 2022 · retrieved 25 Oct 2026 · kept permanently by the SEC · fingerprint 55b15ff4ce92
    “In January of 2022 we initiated our third clinical trial. This new trial is a randomized, double blind, placebo controlled study of safety and efficacy of SBP-101” ✓ confirmed on the page

Checked 25 Oct 2026.

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type
Clinical milestone
Indicative materiality
Medium rules
Action
Initiate
Deliverable
randomized clinical trial
In the company’s control
Medium
Specificity
Medium
Conditional
Yes: working with the FDA
Depends on
Regulatory

How this entry was checked

  1. Commitment recordedThe company's words were matched word for word against the filing.
  2. First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
  3. Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.

Confirmed. This outcome counts towards the company's Kept Score. How verification works

Are you Panbela Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.

Report an error in this entry Reference: KI-C-2021-C029125-023470 · Corrections policy

The Deadline Report

One email a week: the corporate commitments that came due, which were met, which slipped, and what is due next. Free. Stop any time.

No advertising. We never sell or share your address.